Beam Therapeutics

BEAM · NASDAQ

$24.93+$0.74 (+3.06%)TodayMarket closed · Oct 20, 7:58 PM ET

Prev close $24.19

BEAM analyst rating

BuyConsensus of 9 analysts over the last 12 months. 78% rate it a buy.

Strong buy0
Buy7
Hold2
Underperform0
Sell0

12-month price target · 17 analysts

Average $52.26 (+109.6% upside)

Low: $26.26
Now: $24.93
High: $84.00

Upgrades and downgrades

The latest rating actions, newest first

BEAM analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Oct 15, 2026	Maintains	Buy	$80.00	33%
Wedbush	Oct 14, 2026	Maintains	Outperform	$65.00	46%
Wedbush	Sep 9, 2026	Maintains	Outperform	$65.00	46%
HC Wainwright & Co.	Aug 25, 2026	Maintains	Buy	$80.00	33%
B of A Securities	Jul 8, 2026	Maintains	Buy	$47.00	36%
HC Wainwright & Co.	Jul 7, 2026	Maintains	Buy	$80.00	33%
Bernstein	May 13, 2026	Maintains	Outperform	$40.00 → $39.00	52%
Citigroup	Mar 26, 2026	Maintains	Buy	$64.00 → $68.00	36%
RBC Capital	Feb 25, 2026	Maintains	Sector Perform	$22.00 → $26.00	44%
Wedbush	Feb 25, 2026	Maintains	Outperform	$57.00 → $65.00	46%

The case for and against

Updated Oct 15, 2026

Bull case

Beam Therapeutics is viewed positively because BEAM-302 is showing durable single-dose correction in AATD, with 18-month follow-up, 29 efficacy-evaluable patients, and total AAT held above the 11 µM protective threshold while 93% of circulating AAT was corrected M-AAT at 60 mg. Its broader thesis is strengthened by a pivotal cohort already dosing in July, rapid enrollment expectations, and a differentiated platform that appears to restore functional protein rather than merely raise total AAT, alongside in-house manufacturing advantages in risto-cel for SCD. Financially, the company’s $1.15B to ~$1.2B cash position and runway into mid-2029 support development through a catalyst-rich period that includes a possible year-end 2026 BLA filing and a 2H26 pivotal setup.

Bear case

Beam Therapeutics is exposed to substantial fundamental risk because its valuation depends heavily on unproven clinical programs, and poorer-than-expected preclinical or clinical data for BEAM-101, BEAM-302, BEAM-103, or BEAM-104 could signal broader safety issues such as off-target activity. The company’s probabilities of success are modest—45% for BEAM-101 and BEAM-103/104 in SCD, and 30% for BEAM-302 in AATD and BEAM-301 in GSDIa—while competitive pressure, reimbursement uncertainty, and novel-modality risk could further compress market potential. In addition, projected annual gross capital raises of $200M from 2027E to 2030E imply meaningful dilution, reinforcing a weak long-term risk/reward profile.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.